|
Press Releases |
|
|
|
Tuesday, October 3, 2023 |
|
HanchorBio Announces First Patient Dosed in the Phase 1 Multi-Regional Clinical Trial of HCB101 |
more info >> |
|
Monday, August 28, 2023 |
|
HanchorBio and Henlius Announce Strategic Collaboration to Develop Innovative Immunotherapies |
HanchorBio and Henlius Announce Strategic Collaboration to Develop Innovative Immunotherapies more info >> |
|
HanchorBio and Henlius Announce Strategic Collaboration to Develop Innovative Immunotherapies |
HanchorBio and Henlius Announce Strategic Collaboration to Develop Innovative Immunotherapies more info >> |
|
Monday, July 24, 2023 |
|
HanchorBio Announces Taiwan FDA IND Approval for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies |
HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today that the Taiwan Food and Drug Administration (TFDA) has approved its investigational new drug (IND) application to initiate a multi-regional clinical trial of its independently-developed novel drug candidate, HCB101, for the treatment of patients with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma. more info >> |
|
HanchorBio Announces Taiwan FDA IND Approval for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies |
HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today that the Taiwan Food and Drug Administration (TFDA) has approved its investigational new drug (IND) application to initiate a multi-regional clinical trial of its independently-developed novel drug candidate, HCB101, for the treatment of patients with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma. more info >> |
|
Monday, April 17, 2023 |
|
HanchorBio Announces US IND Clearance for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies |
more info >> |
|
HanchorBio Announces US IND Clearance for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies |
HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today that the US. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to initiate a multi-regional clinical trial of its independently-developed novel drug candidate, HCB101, for the treatment of patients with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
TechGALA 2025 - 愛知縣首屆國際初創企業大會
Dec 27, 2024 13:25 HKT/SGT
|
|
|
亨利加集團舉辦更名誌慶暨香港交易所中午開市儀式
Dec 27, 2024 13:20 HKT/SGT
|
|
|
吳佩慈男友紀曉波發聲明 否認參與緬甸「恒升園區」
Dec 27, 2024 13:10 HKT/SGT
|
|
|
The General Incorporated Association Generative AI Japan Announces the Winners of the Japan Generative AI Award 2024
Dec 27, 2024 11:00 JST
|
|
|
MHI Included in "World Index" of Dow Jones Sustainability Index for Second Consecutive Year
Dec 27, 2024 9:36 JST
|
|
|
ACET Founder Acme Proposes Using Bitcoin Integration to Transform Thailand Economy
Dec 27, 2024 07:00: JST
|
|
|
ACET Founder Acme Proposes Using Bitcoin Integration to Transform Thailand Economy
Dec 27, 2024 06:00 HKT/SGT
|
|
|
錨定高質量可持續增長路線 順豐控股構築長期主義價值底色
Dec 26, 2024 22:52 HKT/SGT
|
|
|
锚定高质量可持续增长路线 顺丰控股构筑长期主义价值底色
Dec 26, 2024 22:38 HKT/SGT
|
|
|
三菱重工、ESG投資指標「Dow Jones Sustainability Index(DJSI)」における「World Index」の構成銘柄に2年連続で選定
Dec 26, 2024 18:00: JST
|
|
|
TOYOTA GAZOO Racing to Exhibit at Tokyo Auto Salon 2025
Dec 26, 2024 17:11 JST
|
|
|
Annual Surge of 37% in Legal and Compliance Job Roles while overall hiring drops 6% in Singapore: foundit Insights Tracker
Dec 26, 2024 13:45 HKT/SGT
|
|
|
JCB Launches Red Guahan Shopping Mall Shuttle Free Ride Promotion in Guam
Dec 26, 2024 12:00 JST
|
|
|
Mazda Production and Sales Results for November 2024
Dec 26, 2024 11:46 JST
|
|
|
MHI Conducts Nighttime and Long-Distance Highway Demonstration Testing of Unmanned Aerial Vehicle Currently Under Development
Dec 26, 2024 9:47 JST
|
|
|
|
More News >> |
|
|
|
|
|